<DOC>
	<DOC>NCT00467428</DOC>
	<brief_summary>The purpose of the study is to investigate if NS2359 is effective in the treatment of ADHD in adult patients.</brief_summary>
	<brief_title>Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Patients with the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by DSMIV, as manifested in clinical evaluation and confirmed by structured interview using the KSADSE adult ADHD module Patients with a CGI Global Severity (GS) score â‰¥4 (moderate impairment) The Patient provided written informed consent. Nonlactating women of childbearing potential that used adequate contraception (i.e. the use of oral contraceptives and practising a doublebarrier form of birth control) and had a negative pregnancy test at screening. Women of no childbearing potential who had been postmenopausal for less than 2 years must have a negative pregnancy test at screening. Any clinically unstable medical condition Clinically significant abnormal baseline laboratory values Mental retardation Organic brain disorders Nonfebrile seizure disorder Patients with a history of an eating disorder including anorexia or bulimia nervosa Psychotic disorder of any type Patients with a HAMD (17 item) &gt;15 Patients currently (within the past 6 months) known to abuse or to be dependent on any drug, including alcohol or a positive urine drug screen for cocaine, heroin, or marijuana Treatment with stimulants was prohibited within 1 week prior to randomisation Treatment with antipsychotics/neuroleptics was prohibited for 8 weeks prior to randomisation Treatment with monoamine oxidase inhibitors was prohibited for 8 weeks prior to randomisation Treatment with tricyclic antidepressants, histamines and selective serotonin reuptake inhibitors was prohibited for 4 weeks (fluoxetine for 6 weeks) prior to randomisation Treatment with benzodiazepines, anticonvulsants (for behaviour) and lithium for 2 weeks prior to randomisation Patients with a history of bipolar disorder Patients using any concurrent medication for the treatment of ADHD Patients that had previously participated in a NS2359 study Patients treated with an investigational drug within 30 days or 5 halflives (whichever is longer) preceding the first dose of study medication Patients with a history of positive human immunodeficiency virus (HIV) test.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>ADHD</keyword>
</DOC>